Muscular Atrophy News and Research

RSS

WSU researcher receives $418,000 NINDS grant to study spinal muscular atrophy

Graham Parker, Ph.D., assistant professor of research in the Department of Pediatrics at Wayne State University's School of Medicine, was awarded $418,000 from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health to study how a particular gene might be involved in the progression of spinal muscular atrophy (SMA) - the number one genetic killer of children younger than 2 years old.

12 Sep 2011

Two ALS-associated genes work in tandem to support long-term survival of motor neurons

Although several genes have been linked to amyotrophic lateral sclerosis (ALS), it is still unknown how they cause this progressive neurodegenerative disease. In a new study, Columbia University Medical Center (CUMC) researchers have demonstrated that two ALS-associated genes work in tandem to support the long-term survival of motor neurons.

2 Sep 2011

MDA announces $13.7M in grants to 40 new muscular dystrophy research initiatives

The Muscular Dystrophy Association today announced funding, totaling $13.7 million, for 40 new research initiatives targeting nearly two dozen progressive neuromuscular diseases.

24 Aug 2011

NIH/NINDS awards AMRI to develop pre-clinical drug candidate for spinal muscular atrophy

AMRI today announced it received a federal contract award from the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) to provide chemistry and other drug discovery technologies in support of NINDS' Medicinal Chemistry for Neurotherapeutics Program (MCNP), part of the NIH Blueprint Neurotherapeutics Network.

19 Aug 2011

Repligen first quarter total revenue increases 9% to $7,654,000

Repligen Corporation today reported results for the first quarter of fiscal year 2012, ended June 30, 2011.

27 Jul 2011

New hope for infants born with Spinal Muscular Atrophy

Researchers in Ottawa report new hope for the treatment of infants born with serious genetic disorder.

26 Jul 2011

FDA grants Fast Track designation for Repligen's RG3039 to treat Spinal Muscular Atrophy

Repligen Corporation announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RG3039, a potential treatment for Spinal Muscular Atrophy.

23 Jun 2011

Progressive strength training counteracts muscular atrophy in old age

People lose 30% of their muscle strength between the ages of 50 and 70 years. However, maintaining muscle strength in old age is enormously important in order to maintain mobility and to be able to lead an independent life and manage everyday tasks independently.

10 Jun 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen Corporation today reported results for the fourth quarter and fiscal year 2011, ended March 31, 2011.

9 Jun 2011

New research on spinal muscular atrophy

Spinal muscular atrophy (SMA) is the leading genetic cause of death in children under 2, with no treatment other than supportive care. In the Proceedings of the National Academy of Sciences, researchers at Children's Hospital Boston show how loss or mutation of the SMA gene causes progressive muscle degeneration and weakness, and suggest a promising approach to treating the condition, sometimes referred to as a "Lou Gehrig's disease of babies."

8 Jun 2011

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

PsychoGenics Inc. today announced that it has entered into a strategic alliance with Evotec AG to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies.

25 May 2011

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Repligen Corporation announced today that it has received approval from the Food and Drug Administration to initiate a Phase 1 clinical trial of RG3039, a potential treatment for Spinal Muscular Atrophy.

19 May 2011

Caliper first quarter revenue increases 25% to $35.8 million

Caliper Life Sciences, Inc., today reported its financial results for the first quarter of 2011. First quarter revenue increased to $35.8 million, or 25%, from $28.7 million in the same period of 2010.

2 May 2011

FightSMA to host panel discussions on spinal muscular atrophy

International non-profit organization FightSMA will be hosting highly respected experts from across the country on Thursday, May 5, 2011 for a series of panel discussions, Thriving with SMA: LIVE!.

30 Apr 2011

Repligen anticipates 30% increase in total revenues for 2011

Repligen Corporation today announced preliminary financial results for fiscal year 2011 which ended March 31, 2011. Total revenue for the year is expected to be $27.3 million compared to $21.0 million in the prior fiscal year, an increase of 30%.

21 Apr 2011

Quest Diagnostics completes Athena Diagnostics acquisition

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced it has completed its previously announced acquisition of Athena Diagnostics, an esoteric laboratory specializing in genetic testing for neurological disorders, from Thermo Fisher Scientific.

From Quest Diagnostics 4 Apr 2011

Enzo Life Sciences introduces ELISA system to detect SMN protein

Enzo Biochem, Inc. and the Spinal Muscular Atrophy Foundation today announced that Enzo's wholly owned subsidiary, Enzo Life Sciences Inc., has launched a unique immunoassay system which can be used for the identification and detection of Survival Motor Neuron protein.

16 Mar 2011

Top-line results from Repligen RG2417 Phase 2b trial results in patients with bipolar depression

Repligen Corporation announced today results of a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.

8 Mar 2011

Pluristem's PLX cells exhibit potential to treat accidental and intentionally induced muscle injuries

Pluristem Therapeutics, Inc. and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), in cooperation with the Charite - University of Medicine in Berlin,today announced the results of a pre-clinical study demonstrating that the local administration of PLX cells following muscle injury resulted in significant improvement in the recovery of muscle function when compared with the control group. This

2 Mar 2011

Scientists discover new way to generate human motor nerve cells

Scientists have discovered a new way to generate human motor nerve cells in a development that will help research into motor neurone disease.